發(fā)布時(shí)間：2019-04-03 16:37

【摘要】：目的探討經(jīng)導(dǎo)管肝動(dòng)脈化療栓塞術(shù)(TACE)聯(lián)合利卡汀治療對(duì)肝癌患者病理指標(biāo)及循環(huán)腫瘤細(xì)胞(CTCs)檢出數(shù)的影響。方法選取2014年1月-2016年6月在沭陽(yáng)中山醫(yī)院介入科接受治療的120例原發(fā)性肝癌患者作為該研究對(duì)象。根據(jù)患者治療意愿將其分為對(duì)照組和實(shí)驗(yàn)組,其中對(duì)照組52例,僅給予經(jīng)導(dǎo)管肝動(dòng)脈化療栓塞術(shù)治療,實(shí)驗(yàn)組68例,在對(duì)照組治療基礎(chǔ)上聯(lián)合利卡汀治療。比較兩組患者治療前后腫塊大小、甲胎蛋白(AFP)水平、血象、肝功能、CTCs以及CD147不同分子表型患者。結(jié)果治療后兩組患者腫瘤大小相比差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后,兩組AFP水平比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05),實(shí)驗(yàn)組低于對(duì)照組;治療后,兩組白細(xì)胞計(jì)數(shù)和丙氨酸轉(zhuǎn)氨酶比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05),白細(xì)胞計(jì)數(shù)實(shí)驗(yàn)組低于對(duì)照組,丙氨酸轉(zhuǎn)氨酶實(shí)驗(yàn)組高于對(duì)照組;治療后兩組CTCs檢出數(shù)目比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05),均降低,且實(shí)驗(yàn)組低于對(duì)照組;實(shí)驗(yàn)組CD147 2種表型患者治療前后CTCs數(shù)目變化值間比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05);對(duì)照組CD147 2種表型患者治療前后CTCs數(shù)目變化值間比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);兩組患者不良反應(yīng)發(fā)生率比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論利卡汀聯(lián)合TACE治療肝癌,臨床效果優(yōu)于單純TACE治療,此外,利卡汀對(duì)于CD147~+肝癌患者治療效果優(yōu)于CD147~-患者。
[Abstract]:Objective To study the effect of transcatheter hepatic arterial chemoembolization (TACE) on the pathological index and the number of circulating tumor cells (CTCs) in patients with liver cancer. Methods 120 patients with primary liver cancer who received the treatment in the interventional department of Zhongshan Hospital from January 2014 to June 2016 were selected as the subject of the study. The control group and the experimental group were divided into the control group and the experimental group according to the patient's treatment intention. The size of mass, alpha-fetoprotein (AFP), blood image, liver function, CTCs and CD147 were compared between the two groups. Results There was no significant difference in the tumor size of the two groups after the treatment (P0.05). After the treatment, the levels of AFP in the two groups were statistically significant (P0.05), and the experimental group was lower than that of the control group. After the treatment, the two groups of white blood cell count and the alanine aminotransferase were compared. The difference was significant (P0.05). The experimental group of the white blood cell count was lower than that of the control group, and the experimental group of the alanine aminotransferase was higher than that of the control group. The number of CTCs in the two groups was significantly lower than that of the control group (P0.05), and the experimental group was lower than that of the control group. There was no significant difference between the changes in the number of CTCs before and after the treatment of CD147 in the experimental group (P <0.05), and the difference in the number of CTCs before and after the treatment of CD147 in the control group was not statistically significant (P0.05). The incidence of adverse reactions in the two groups was compared. The difference was not significant (P0.05). Conclusion The clinical effect of Ligabat combined with TACE in the treatment of liver cancer is superior to that of single TACE. In addition, the therapeutic effect of liqin on the patients with CD147 ~ + liver cancer is better than that of CD147 ~-patients.
【作者單位】： 江蘇省沭陽(yáng)中山醫(yī)院普外科;上海東方肝膽外科醫(yī)院膽道一科;
【基金】：上海市科學(xué)技術(shù)委員會(huì)科技發(fā)展基金(No:12211967700)
【分類號(hào)】：R735.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 洪德飛;肝癌激光誘導(dǎo)間質(zhì)熱療的研究進(jìn)展[J];國(guó)外醫(yī)學(xué)(腫瘤學(xué)分冊(cè));2002年03期

2 楊甲梅;闞彤;;肝癌的局部微創(chuàng)治療[J];肝膽外科雜志;2008年06期

3 王紅梅;趙秀娟;喬振華;;晚期肝癌化療結(jié)合骨髓間充質(zhì)干細(xì)胞輸注療效觀察[J];臨床醫(yī)藥實(shí)踐;2009年13期

4 王琮;孫一予;李小江;;中藥聯(lián)合熱療在肝癌治療中的應(yīng)用[J];世界中西醫(yī)結(jié)合雜志;2010年09期

5 李波;;復(fù)發(fā)肝癌診治現(xiàn)狀及策略[J];中國(guó)普外基礎(chǔ)與臨床雜志;2013年05期

6 ;肝癌[J];中國(guó)醫(yī)學(xué)文摘.內(nèi)科學(xué);1981年01期

7 王清水，，林鎮(zhèn)和，吳淑貝，王湘英;選擇性肝動(dòng)脈插管栓塞化療治療中晚期肝癌33例報(bào)告[J];福建醫(yī)藥雜志;1994年06期

8 楊昆;征服肝癌還有多遠(yuǎn)[J];w攣胖蕓

本文編號(hào)：2453362